|
시장보고서
상품코드
2128159
자궁내막암 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)Endometrial Cancer Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
자궁내막암 시장 성장요인
세계 자궁내막암 시장은 2025년 26억 6,000만 달러로 평가되며, 2026년 30억 1,000만 달러에서 2034년까지 79억 달러로 성장하여, 예측 기간 동안 연평균 성장률(CAGR)은 12.84%에 달할 것으로 전망됩니다. 북미는 선진적인 의료 인프라, 면역요법의 도입 확대, 바이오마커 검사의 보급, 그리고 유리한 보험 환급 정책에 힘입어 2025년 46.61%의 시장 점유율을 차지하며 세계 시장을 선도했습니다.
자궁내막암은 전 세계 여성에게 영향을 미치는 가장 흔한 부인과 악성 종양 중 하나입니다. 이 시장에는 조기, 진행성, 재발성 및 전이성 질환에 대한 치료법이 포함되어 있으며, 치료 전략은 점차 정밀 의학 및 면역요법을 기반으로 한 병용요법으로 전환되고 있습니다. 제약사들은 환자의 예후를 개선하고 치료 선택지를 확대하기 위해 연구 개발, 임상시험 및 규제 당국의 승인 획득에 적극적으로 투자하고 있습니다. 이 질환의 유병률 증가와 분자진단 기술의 발전이 맞물려 업계에 계속해서 강력한 성장 기회를 창출하고 있습니다.
면역요법과 정밀의료의 확산이 시장 성장을 견인
의료 서비스 제공자들이 맞춤형 치료를 위한 바이오마커 기반 치료법을 점점 더 많이 채택함에 따라 시장은 큰 변화를 겪고 있습니다. PD-1 억제제, 표적 치료 및 병용요법은 진행성 및 재발성 자궁내막암의 우선적인 치료 선택지가 되고 있습니다. 면역요법 병용요법에 대한 승인 범위가 확대됨에 따라 더 많은 환자가 혁신적인 치료를 받을 수 있게 되었고, 이로 인해 시장 전체의 성장이 가속화되고 있습니다.
신규 면역종양학 치료법 개발 증가가 주요 시장 동향으로 부상
자궁내막암 시장을 형성하는 주요 동향 중 하나는 혁신적인 면역종양학 치료법, 항체약물접합체(ADC), 표적 치료제의 파이프라인이 확대되고 있다는 점입니다. 제약사들은 재발 사례나 바이오마커로 정의된 질환을 가진 환자의 미충족 의료 수요에 대응하기 위해 임상 개발 프로그램을 확대하고 있습니다. HER2 양성, dMMR/MSI-H 및 pMMR 환자 집단에 대한 관심이 높아지고 있는 것은 맞춤형 암 치료로의 전환을 뒷받침하며, 장기 생존율 향상으로 이어지고 있습니다.
시장 촉진요인
자궁내막암 발병률의 증가는 여전히 시장의 주요 성장 요인으로 작용하고 있습니다. 고령화, 비만, 당뇨병, 대사성 질환 등의 요인이 전 세계 진단율 상승에 기여하고 있습니다. 고도의 치료가 필요한 환자가 늘어남에 따라, 병원 및 암 센터에서는 분자 검사, 면역요법, 분자 표적 치료제에 대한 접근성을 확대하고 있습니다. 지속적인 제품 승인 및 적응증 확대는 의료진에게 더 효과적인 치료 옵션을 제공함으로써 시장 수요를 더욱 강화하고 있습니다.
시장 제약요인
급속한 기술 혁신이 진행되고 있음에도 불구하고, 첨단 치료법의 높은 비용이 여전히 시장 확대를 제한하고 있습니다. 면역요법 병용요법, 표적 치료제, 바이오마커 검사 및 환자의 장기 모니터링은 치료비를 대폭 증가시킵니다. 개발도상국이나 비용에 민감한 의료 시스템의 경우, 보험 급여 제한으로 인해 임상적 유효성이 입증되었음에도 불구하고 고가의 치료법 도입이 지연되고, 환자의 접근성이 제한되는 경우가 많습니다.
시장 기회
바이오마커 기반 치료 전략의 확대는 시장에 진입하는 기업들에게 큰 성장 기회를 제공하고 있습니다. 정밀 의학을 통해 의사는 분자적 특성에 따라 치료법을 선택할 수 있게 되어, 치료 반응과 환자의 생존율이 향상됩니다. 제약사들은 HER2 발현, MSI-H, dMMR 및 pMMR 환자 집단을 대상으로 한 표적 치료제 개발을 점점 더 적극적으로 추진하고 있으며, 이는 맞춤형 암 치료를 지원하는 동시에 새로운 상업적 기회를 창출하고 있습니다.
세분화 분석
약제 분류별로는 PD-1 억제제가 진행성 및 재발성 자궁내막암에서 임상적 유효성이 입증됨에 따라 2025년에는 시장을 주도했습니다. 광범위한 승인 범위, 우수한 생존 성과, 그리고 화학요법과의 병용 사용 증가가 이 부문의 성장을 더욱 뒷받침하고 있습니다. PD-L1 억제제 부문은 예측 기간 동안 가장 빠른 성장이 예상됩니다.
암 유형별로는 자궁내막양 선암이 전 세계에서 진단되는 자궁체부암 사례의 대부분을 차지하고 있어 가장 큰 시장 점유율을 기록했습니다. 환자 수가 많고, 수술, 화학요법, 면역요법, 호르몬요법의 광범위한 사용이 이러한 주도적인 위치를 뒷받침하고 있습니다.
치료법별로는 2025년에도 화학요법이 여전히 주요 치료 부문을 차지하고 있습니다. 이는 면역요법과 병용되는 경우에도 백금 제제 및 탁산계 약물을 이용한 요법이 표준 1차 치료의 기반으로 계속 기능하고 있기 때문입니다. 그러나 승인 건수의 증가와 의료진의 수용 확대에 따라 면역요법이 가장 높은 성장률을 보일 것으로 예상됩니다.
전문가의 감독이 필요한 화학요법 및 면역요법 치료가 병원에서 이루어지기 때문에 유통 채널 부문에서는 병원 약국이 주도적인 위치를 차지했습니다.
지역별 전망
북미는 2025년에 12억 4,000만 달러의 시장 규모를 기록하며 전 세계 자궁내막암 시장을 주도했습니다. 이 지역은 잘 갖춰진 암 의료 인프라, 높은 진단률, 바이오마커 검사의 보급, 그리고 혁신적인 면역요법의 급속한 도입과 같은 요인의 혜택을 받고 있습니다. 미국은 해당 지역의 매출에서 계속해서 가장 큰 기여를 하고 있습니다.
유럽은 규제 당국의 승인 확대, 국가 암 대책 프로그램, 그리고 면역요법을 기반으로 한 병용 치료의 이용 증가에 힘입어 2위 지역 시장이 되었습니다. 독일과 영국은 고도의 암 의료 접근성 개선을 통해 계속해서 지역 성장을 주도하고 있습니다.
아시아태평양은 환자 수 증가, 의료 인프라 개선, 암에 대한 인식 제고, 그리고 최신 종양 치료의 보급 확대로 인해 상당한 성장이 예상됩니다. 중국, 일본, 인도는 예측 기간 동안 주요 성장 시장으로 남아 있을 것으로 예상됩니다.
라틴아메리카 및 중동 및 아프리카에서는 의료 투자 증가, 암 진단 기술의 향상, 신흥 경제국 전반에 걸친 첨단 치료에 대한 접근성이 점차 확대됨에 따라 꾸준한 성장이 예상됩니다.
2026년 4월, BioNTech사는 HER2 발현을 동반한 진행성 자궁내막암에 대한 트라스투주맙 파밀테칸의 2상 임상시험에서 긍정적인 결과를 발표했습니다. 같은 달, Utepreva LLC는 조기 진단 향상을 목적으로 FDA 승인을 받은 자궁내막 샘플링 장치를 출시했습니다. 2024년 8월, GSK는 진행성 또는 재발성 자궁내막암에 대한 젠펠리와 카보플라틴 및 파클리탁셀 병용요법에 대해 미국 FDA의 승인을 획득하여 면역요법의 치료 선택지를 더욱 확대했습니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 자궁내막암 시장 분석, 인사이트, 예측, 2021-2034년
제6장 북미의 자궁내막암 시장 분석, 인사이트, 예측, 2021-2034년
제7장 유럽의 자궁내막암 시장 분석, 인사이트, 예측, 2021-2034년
제8장 아시아태평양의 자궁내막암 시장 분석, 인사이트, 예측, 2021-2034년
제9장 중동 및 아프리카의 자궁내막암 시장 분석, 인사이트, 예측, 2021-2034년
제10장 경쟁 분석
KSMGrowth Factors of endometrial cancer Market
The global endometrial cancer market was valued at USD 2.66 billion in 2025 and is projected to grow from USD 3.01 billion in 2026 to USD 7.90 billion by 2034, registering a CAGR of 12.84% during the forecast period. North America dominated the global market with a 46.61% market share in 2025, supported by advanced healthcare infrastructure, increasing adoption of immunotherapy, widespread biomarker testing, and favorable reimbursement policies.
Endometrial cancer is one of the most common gynecologic malignancies affecting women worldwide. The market includes therapies for early-stage, advanced, recurrent, and metastatic disease, with treatment strategies increasingly shifting toward precision medicine and immunotherapy-based combinations. Pharmaceutical companies are actively investing in research and development, clinical trials, and regulatory approvals to improve patient outcomes and expand treatment options. The growing incidence of the disease, coupled with advancements in molecular diagnostics, continues to create strong growth opportunities for the industry.
Growing Adoption of Immunotherapy and Precision Medicine Drives Market Growth
The market is experiencing significant transformation as healthcare providers increasingly adopt biomarker-guided therapies for personalized treatment. PD-1 inhibitors, targeted therapies, and combination regimens are becoming the preferred treatment options for advanced and recurrent endometrial cancer. Expanded regulatory approvals for immunotherapy combinations are enabling more patients to access innovative treatments, thereby accelerating overall market growth.
Rising Development of Novel Immuno-Oncology Therapies Emerges as a Key Market Trend
One of the major trends shaping the endometrial cancer market is the growing pipeline of innovative immuno-oncology therapies, antibody-drug conjugates, and targeted medicines. Pharmaceutical companies are expanding clinical development programs to address unmet needs among patients with recurrent or biomarker-defined disease. The increasing focus on HER2-positive, dMMR/MSI-H, and pMMR patient populations is supporting the transition toward personalized cancer care and improving long-term survival outcomes.
Market Drivers
The rising incidence of endometrial cancer remains the primary growth driver for the market. Factors such as aging populations, obesity, diabetes, and metabolic disorders are contributing to increasing diagnosis rates worldwide. As more patients require advanced treatment, hospitals and oncology centers are expanding access to molecular testing, immunotherapy, and targeted medicines. Continuous product approvals and label expansions further strengthen market demand by providing physicians with more effective treatment options.
Market Restraints
Despite rapid innovation, the high cost of advanced therapies continues to limit market expansion. Immunotherapy combinations, targeted drugs, biomarker testing, and long-term patient monitoring significantly increase treatment expenses. In developing countries and cost-sensitive healthcare systems, reimbursement limitations often delay the adoption of premium therapies, restricting patient access despite demonstrated clinical benefits.
Market Opportunities
The expansion of biomarker-guided treatment strategies presents significant growth opportunities for market participants. Precision medicine enables physicians to select therapies based on molecular characteristics, improving treatment response and patient survival. Pharmaceutical companies are increasingly developing targeted therapies for HER2-expressing, MSI-H, dMMR, and pMMR patient populations, creating new commercial opportunities while supporting personalized oncology care.
Segmentation Analysis
Based on drug class, PD-1 inhibitors dominated the market in 2025 due to their proven clinical effectiveness in advanced and recurrent endometrial cancer. Their broad regulatory approvals, strong survival outcomes, and increasing use alongside chemotherapy continue to strengthen segment growth. The PD-L1 inhibitors segment is expected to witness the fastest expansion during the forecast period.
By cancer type, endometrioid adenocarcinoma accounted for the largest market share because it represents the majority of diagnosed endometrial cancer cases worldwide. The large patient population and broad use of surgery, chemotherapy, immunotherapy, and hormonal therapy support its leading position.
Based on therapy, chemotherapy remained the dominant treatment segment in 2025, as platinum-taxane regimens continue to serve as the standard first-line treatment backbone, even when combined with immunotherapy. However, immunotherapy is expected to register the highest growth due to increasing approvals and wider physician acceptance.
Hospital pharmacies dominated the distribution channel segment owing to the hospital-based administration of chemotherapy and immunotherapy treatments requiring specialist supervision.
Regional Outlook
North America led the global endometrial cancer market with a valuation of USD 1.24 billion in 2025. The region benefits from strong oncology infrastructure, high diagnosis rates, widespread biomarker testing, and rapid adoption of innovative immunotherapies. The U.S. remains the largest contributor to regional revenue.
Europe represents the second-largest regional market, supported by expanding regulatory approvals, national cancer programs, and increasing use of immunotherapy-based treatment combinations. Germany and the U.K. continue to drive regional growth through improved access to advanced oncology care.
Asia Pacific is projected to experience substantial growth due to its expanding patient population, improving healthcare infrastructure, increasing cancer awareness, and rising availability of modern oncology treatments. China, Japan, and India are expected to remain key growth markets throughout the forecast period.
Latin America and the Middle East & Africa are anticipated to record steady growth as healthcare investments increase, cancer diagnosis improves, and access to advanced therapies gradually expands across emerging economies.
Competitive Landscape
The global endometrial cancer market is moderately consolidated, with major companies investing heavily in research, biomarker-based drug development, regulatory approvals, and strategic collaborations. Leading companies include Merck & Co., Inc., Eisai Co., Ltd., GSK plc, AstraZeneca PLC, Pfizer Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Accord Healthcare Limited, and Bristol Myers Squibb Company. Ongoing clinical trials, product launches, and label expansions continue to strengthen competition across the market.
Recent Industry Developments
In April 2026, BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing advanced endometrial cancer. During the same month, Utepreva LLC launched an FDA-cleared endometrial sampling device designed to improve early diagnosis. In August 2024, GSK received U.S. FDA approval for Jemperli combined with carboplatin and paclitaxel for advanced or recurrent endometrial cancer, further expanding immunotherapy treatment options.
Conclusion
The global endometrial cancer market is expected to witness strong growth through 2034, driven by rising disease incidence, increasing adoption of precision medicine, expanding biomarker testing, and continuous innovation in immunotherapy and targeted therapies. With growing investments in research and development, favorable regulatory approvals, and broader access to personalized treatment approaches, the market is well-positioned for sustained expansion between 2026 and 2034.
Segmentation By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Region
By Drug Class * PD-1 Inhibitors
- Platinum Compounds
- Taxanes
- VEGFR/Multikinase Inhibitors
- Progestins
- PD-L1 Inhibitors
- Others
By Cancer Type * Endometrioid Adenocarcinoma
- Serous Endometrial Carcinoma
- Clear Cell Carcinoma
- Carcinosarcoma
- Others
By Age Group * Pediatric
- Adults
By Therapy * Chemotherapy
- Immunotherapy
- Targeted Therapy
- Hormonal Therapy
- Others
By Route of Administration * Oral
- Parenteral
By Distribution Channel * Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Specialty Pharmacies
By Region * North America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 3.5. Market Challenges
4. Key Insights
- 4.1. Prevalence of Endometrial Cancer, By Countries/Region, 2025
- 4.2. New Product Launches, By Key Players
- 4.3. Overview of Regulatory Scenario, By Key Regions/ Countries
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.5. Pipeline Analysis, By Key Players
5. Global Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. PD-1 Inhibitors
- 5.1.2. Platinum Compounds
- 5.1.3. Taxanes
- 5.1.4. VEGFR/Multikinase Inhibitors
- 5.1.5. Progestins
- 5.1.6. PD-L1 Inhibitors
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Cancer Type
- 5.2.1. Endometrioid Adenocarcinoma
- 5.2.2. Serous Endometrial Carcinoma
- 5.2.3. Clear Cell Carcinoma
- 5.2.4. Carcinosarcoma
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
- 5.4. Market Analysis, Insights and Forecast - By Therapy
- 5.4.1. Chemotherapy
- 5.4.2. Immunotherapy
- 5.4.3. Targeted Therapy
- 5.4.4. Hormonal Therapy
- 5.4.5. Others
- 5.5. Market Analysis, Insights and Forecast - By Route of Administration
- 5.5.1. Oral
- 5.5.2. Parenteral
- 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.6.1. Hospital Pharmacies
- 5.6.2. Drug Stores & Retail Pharmacies
- 5.6.3. Online Pharmacies
- 5.6.4. Specialty Pharmacies
- 5.7. Market Analysis, Insights and Forecast - Region
- 5.7.1. North America
- 5.7.2. Europe
- 5.7.3. Asia Pacific
- 5.7.4. Latin America
- 5.7.5. Middle East & Africa
6. North America Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. PD-1 Inhibitors
- 6.1.2. Platinum Compounds
- 6.1.3. Taxanes
- 6.1.4. VEGFR/Multikinase Inhibitors
- 6.1.5. Progestins
- 6.1.6. PD-L1 Inhibitors
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast - By Cancer Type
- 6.2.1. Endometrioid Adenocarcinoma
- 6.2.2. Serous Endometrial Carcinoma
- 6.2.3. Clear Cell Carcinoma
- 6.2.4. Carcinosarcoma
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adults
- 6.4. Market Analysis, Insights and Forecast - By Therapy
- 6.4.1. Chemotherapy
- 6.4.2. Immunotherapy
- 6.4.3. Targeted Therapy
- 6.4.4. Hormonal Therapy
- 6.4.5. Others
- 6.5. Market Analysis, Insights and Forecast - By Route of Administration
- 6.5.1. Oral
- 6.5.2. Parenteral
- 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.6.1. Hospital Pharmacies
- 6.6.2. Drug Stores & Retail Pharmacies
- 6.6.3. Online Pharmacies
- 6.6.4. Specialty Pharmacies
- 6.7. Market Analysis, Insights and Forecast - By Country
- 6.7.1. U.S.
- 6.7.2. Canada
7. Europe Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. PD-1 Inhibitors
- 7.1.2. Platinum Compounds
- 7.1.3. Taxanes
- 7.1.4. VEGFR/Multikinase Inhibitors
- 7.1.5. Progestins
- 7.1.6. PD-L1 Inhibitors
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast - By Cancer Type
- 7.2.1. Endometrioid Adenocarcinoma
- 7.2.2. Serous Endometrial Carcinoma
- 7.2.3. Clear Cell Carcinoma
- 7.2.4. Carcinosarcoma
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adults
- 7.4. Market Analysis, Insights and Forecast - By Therapy
- 7.4.1. Chemotherapy
- 7.4.2. Immunotherapy
- 7.4.3. Targeted Therapy
- 7.4.4. Hormonal Therapy
- 7.4.5. Others
- 7.5. Market Analysis, Insights and Forecast - By Route of Administration
- 7.5.1. Oral
- 7.5.2. Parenteral
- 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.6.1. Hospital Pharmacies
- 7.6.2. Drug Stores & Retail Pharmacies
- 7.6.3. Online Pharmacies
- 7.6.4. Specialty Pharmacies
- 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.7.1. U.K.
- 7.7.2. Germany
- 7.7.3. France
- 7.7.4. Italy
- 7.7.5. Spain
- 7.7.6. Scandinavia
- 7.7.7. Rest of Europe
8. Asia Pacific Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. PD-1 Inhibitors
- 8.1.2. Platinum Compounds
- 8.1.3. Taxanes
- 8.1.4. VEGFR/Multikinase Inhibitors
- 8.1.5. Progestins
- 8.1.6. PD-L1 Inhibitors
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast - By Cancer Type
- 8.2.1. Endometrioid Adenocarcinoma
- 8.2.2. Serous Endometrial Carcinoma
- 8.2.3. Clear Cell Carcinoma
- 8.2.4. Carcinosarcoma
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adults
- 8.4. Market Analysis, Insights and Forecast - By Therapy
- 8.4.1. Chemotherapy
- 8.4.2. Immunotherapy
- 8.4.3. Targeted Therapy
- 8.4.4. Hormonal Therapy
- 8.4.5. Others
- 8.5. Market Analysis, Insights and Forecast - By Route of Administration
- 8.5.1. Oral
- 8.5.2. Parenteral
- 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.6.1. Hospital Pharmacies
- 8.6.2. Drug Stores & Retail Pharmacies
- 8.6.3. Online Pharmacies
- 8.6.4. Specialty Pharmacies
- 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.7.1. China
- 8.7.2. Japan
- 8.7.3. India
- 8.7.4. Southeast Asia
- 8.7.5. Australia
- 8.7.6. Rest of Asia Pacific
- 8.8. Market Analysis, Insights and Forecast - By Drug Class
- 8.8.1. PD-1 Inhibitors
- 8.8.2. Platinum Compounds
- 8.8.3. Taxanes
- 8.8.4. VEGFR/Multikinase Inhibitors
- 8.8.5. Progestins
- 8.8.6. PD-L1 Inhibitors
- 8.8.7. Others
- 8.9. Market Analysis, Insights and Forecast - By Cancer Type
- 8.9.1. Endometrioid Adenocarcinoma
- 8.9.2. Serous Endometrial Carcinoma
- 8.9.3. Clear Cell Carcinoma
- 8.9.4. Carcinosarcoma
- 8.9.5. Others
- 8.10. Market Analysis, Insights and Forecast - By Age Group
- 8.10.1. Pediatric
- 8.10.2. Adults
- 8.11. Market Analysis, Insights and Forecast - By Therapy
- 8.11.1. Chemotherapy
- 8.11.2. Immunotherapy
- 8.11.3. Targeted Therapy
- 8.11.4. Hormonal Therapy
- 8.11.5. Others
- 8.12. Market Analysis, Insights and Forecast - By Route of Administration
- 8.12.1. Oral
- 8.12.2. Parenteral
- 8.13. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.13.1. Hospital Pharmacies
- 8.13.2. Drug Stores & Retail Pharmacies
- 8.13.3. Online Pharmacies
- 8.13.4. Specialty Pharmacies
- 8.14. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.14.1. Brazil
- 8.14.2. Mexico
- 8.14.3. Rest of Latin America
9. Middle East & Africa Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. PD-1 Inhibitors
- 9.1.2. Platinum Compounds
- 9.1.3. Taxanes
- 9.1.4. VEGFR/Multikinase Inhibitors
- 9.1.5. Progestins
- 9.1.6. PD-L1 Inhibitors
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast - By Cancer Type
- 9.2.1. Endometrioid Adenocarcinoma
- 9.2.2. Serous Endometrial Carcinoma
- 9.2.3. Clear Cell Carcinoma
- 9.2.4. Carcinosarcoma
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adults
- 9.4. Market Analysis, Insights and Forecast - By Therapy
- 9.4.1. Chemotherapy
- 9.4.2. Immunotherapy
- 9.4.3. Targeted Therapy
- 9.4.4. Hormonal Therapy
- 9.4.5. Others
- 9.5. Market Analysis, Insights and Forecast - By Route of Administration
- 9.5.1. Oral
- 9.5.2. Parenteral
- 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.6.1. Hospital Pharmacies
- 9.6.2. Drug Stores & Retail Pharmacies
- 9.6.3. Online Pharmacies
- 9.6.4. Specialty Pharmacies
- 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.7.1. GCC
- 9.7.2. South Africa
- 9.7.3. Rest of Middle East & Africa
10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles
- 10.2.1. Merck & Co., Inc.
- 10.2.2. Eisai Co., Ltd.
- 10.2.3. GSK plc
- 10.2.4. AstraZeneca PLC
- 10.2.5. Pfizer Inc.
- 10.2.6. Fresenius Kabi AG
- 10.2.7. Hikma Pharmaceuticals PLC
- 10.2.8. Teva Pharmaceutical Industries Ltd.
- 10.2.9. Accord Healthcare Limited
- 10.2.10. Bristol Myers Squibb Company
